新產業(300832.SZ):獲得補體C3測定試劑盒(免疫透射比濁法)醫療器械註冊證
格隆匯11月26日丨新產業(300832.SZ)公佈,公司近日收到廣東省藥品監督管理局頒發的1項《醫療器械註冊證》,產品名稱為補體C3測定試劑盒(免疫透射比濁法),註冊證編號為粵械注準20242401551,有效期為2024年11月21日至2029年11月20日。該試劑盒用於體外定量測定人血清和血漿中補體C3的含量,臨牀上用於補體低下或相關免疫缺陷性疾病的輔助診斷。此次獲證豐富了公司生化檢測產品中"免疫類"項目類別,對公司發展具有正面影響,但對近期的生產經營和業績不會產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.